Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial

por Leder, Benjamin Z, Zapalowski, Carol, Hu, Ming‐Yi, Hattersley, Gary, Lane, Nancy E, Singer, Andrea J, Dore, Robin K
Publicado 2019